Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $2.4 million.

  • Enanta Pharmaceuticals' Change in Accured Expenses rose 502.99% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58,000, marking a year-over-year increase of 101.03%. This contributed to the annual value of $58,000 for FY2025, which is 101.03% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Change in Accured Expenses stood at $2.4 million, which was down 4.16% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Accured Expenses peaked at $4.7 million during Q3 2021, and registered a low of -$6.7 million during Q4 2023.
  • In the last 3 years, Enanta Pharmaceuticals' Change in Accured Expenses had a median value of $547,000 in 2023 and averaged -$140,636.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Change in Accured Expenses surged by 939.85% in 2021, and later plummeted by 277.88% in 2024.
  • Enanta Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $4.2 million in 2021, then crashed by 256.89% to -$6.6 million in 2022, then dropped by 2.08% to -$6.7 million in 2023, then surged by 56.80% to -$2.9 million in 2024, then spiked by 502.99% to $2.4 million in 2025.
  • Its Change in Accured Expenses was $2.4 million in Q3 2025, compared to $2.5 million in Q2 2025 and -$2.0 million in Q1 2025.